Page last updated: 2024-08-18

xanthenes and Parkinsonian Disorders

xanthenes has been researched along with Parkinsonian Disorders in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M1
Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P1
Mitsumoto, Y; Mori, A; Nakai, M; Watanabe, A1

Other Studies

3 other study(ies) available for xanthenes and Parkinsonian Disorders

ArticleYear
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Neuropharmacology, 2013, Volume: 73

    Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes

2013
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
    Journal of neuropathology and experimental neurology, 2009, Volume: 68, Issue:4

    Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes

2009
1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum.
    Experimental neurology, 2003, Volume: 179, Issue:1

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Carbocyanines; Coloring Agents; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluorometry; Male; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Mitochondria; Nerve Tissue Proteins; Oxazines; Oxidation-Reduction; Parkinsonian Disorders; Piperazines; Presynaptic Terminals; Rats; Rats, Wistar; Sodium Cyanide; Synaptosomes; Tyrosine 3-Monooxygenase; Xanthenes

2003